{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,18]],"date-time":"2026-07-18T20:22:44Z","timestamp":1784406164227,"version":"3.55.0"},"reference-count":49,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2018,1,5]],"date-time":"2018-01-05T00:00:00Z","timestamp":1515110400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Brit J Clinical Pharma"],"published-print":{"date-parts":[[2018,3]]},"abstract":"<jats:sec><jats:title>Aims<\/jats:title><jats:p>Topical growth factors accelerate wound healing in patients with diabetic foot ulcers (DFU). Due to the absence of head\u2010to\u2010head comparisons, we carried out Bayesian network meta\u2010analysis to compare the efficacy and safety of growth factors.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Using an appropriate search strategy, randomized controlled trials on topical growth factors compared with standard of care in patients with DFU, were included. Proportion of patients with complete healing was the primary outcome. Odds ratio (95% confidence interval) was used as the effect estimate and random effects model was used for both direct and indirect comparisons. Markov Chain Monte Carlo simulation was used to obtain pooled estimates. Rankogram was generated based on surface under the cumulative ranking curve (SUCRA).<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>A total of 26 studies with 2088 participants and 1018 events were included. The pooled estimates for recombinant epidermal growth factor (rhEGF), autologous platelet rich plasma (PRP), recombinant human platelet\u2010derived growth factor (rhPDGF) were 5.72 [3.34, 10.37], 2.65 [1.60, 4.54] and 1.97 [1.54, 2.55] respectively. SUCRA for rhEGF was 0.95. Sensitivity analyses did not reveal significant changes from the pooled estimates and rankogram. No differences were observed in the overall risk of adverse events between the growth factors. However, the growth factors were observed to lower the risk of lower limb amputation compared to standard of care.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>To conclude, rhEGF, rhPDGF and autologous PRP significantly improved the healing rate when used as adjuvants to standard of care, of which rhEGF may perform better than other growth factors. The strength of most of the outcomes assessed was low and the findings may not be applicable for DFU with infection or osteomyelitis. The findings of this study needs to be considered with caution as the results might change with findings from head\u2010to\u2010head studies.<\/jats:p><\/jats:sec>","DOI":"10.1111\/bcp.13470","type":"journal-article","created":{"date-parts":[[2017,11,17]],"date-time":"2017-11-17T06:56:33Z","timestamp":1510901793000},"page":"434-444","source":"Crossref","is-referenced-by-count":43,"title":["Growth factors for diabetic foot ulcers: mixed treatment comparison analysis of randomized clinical trials"],"prefix":"10.1111","volume":"84","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3811-6503","authenticated-orcid":false,"given":"Kannan","family":"Sridharan","sequence":"first","affiliation":[{"name":"Department of Pharmacology and Therapeutics, College of Medicine and Medical Sciences Arabian Gulf University  Manama Bahrain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5877-205X","authenticated-orcid":false,"given":"Gowri","family":"Sivaramakrishnan","sequence":"additional","affiliation":[{"name":"Department of Oral Health, College of Medicine, Nursing and Health Sciences Fiji National University  Suva Fiji"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2018,1,5]]},"reference":[{"key":"e_1_2_9_2_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc07-1302"},{"key":"e_1_2_9_3_1","doi-asserted-by":"publisher","DOI":"10.1177\/0141076816688346"},{"key":"e_1_2_9_4_1","doi-asserted-by":"publisher","DOI":"10.12968\/jowc.2010.19.8.77711"},{"key":"e_1_2_9_5_1","doi-asserted-by":"publisher","DOI":"10.1080\/07853890.2016.1231932"},{"key":"e_1_2_9_6_1","doi-asserted-by":"publisher","DOI":"10.1007\/s13300-012-0004-9"},{"key":"e_1_2_9_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(05)67698-2"},{"key":"e_1_2_9_8_1","doi-asserted-by":"publisher","DOI":"10.2337\/diacare.27.9.2129"},{"key":"e_1_2_9_9_1","doi-asserted-by":"publisher","DOI":"10.1080\/00015458.2005.11679687"},{"key":"e_1_2_9_10_1","doi-asserted-by":"publisher","DOI":"10.1002\/bjs.4019"},{"key":"e_1_2_9_11_1","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD008548.pub2","article-title":"Growth factors for treating diabetic foot ulcers","author":"Mart\u00ed\u2010Carvajal AJ","year":"2015","journal-title":"Cochrane Database Syst Rev"},{"key":"e_1_2_9_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jclinepi.2009.06.005"},{"key":"e_1_2_9_13_1","volume-title":"Cochrane Handbook for Systematic Reviews of Interventions","author":"Higgins JPT"},{"key":"e_1_2_9_14_1","doi-asserted-by":"publisher","DOI":"10.1186\/2046-4053-3-110"},{"key":"e_1_2_9_15_1","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1186\/s12874-015-0060-8","article-title":"Ranking treatments in frequentist network meta\u2010analysis works without resampling methods","volume":"15","author":"Rucker G","year":"2015","journal-title":"BMC Med Res Methodol"},{"key":"e_1_2_9_16_1","doi-asserted-by":"crossref","first-page":"e9","DOI":"10.4081\/cp.2013.e9","article-title":"Comparative study of different treatment options of grade III and IV diabetic foot ulcers to reduce the incidence of amputations","volume":"3","author":"Khandelwal S","year":"2013","journal-title":"Clin Pract"},{"key":"e_1_2_9_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.avsg.2016.04.023"},{"key":"e_1_2_9_18_1","first-page":"68","article-title":"A prospective, randomized, controlled trial of autologous platelet\u2010rich plasma gel for the treatment of diabetic foot ulcers","volume":"52","author":"Driver VR","year":"2006","journal-title":"Ostomy Wound Manage"},{"key":"e_1_2_9_19_1","doi-asserted-by":"publisher","DOI":"10.1111\/wrr.12187"},{"key":"e_1_2_9_20_1","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1007\/s12262-010-0005-8","article-title":"Efficacy of topical recombinant human platelet derived growth factor on wound healing in patients with chronic diabetic lower limb ulcers","volume":"72","author":"Jaiswal SS","year":"2010","journal-title":"Indian J Surg"},{"key":"e_1_2_9_21_1","doi-asserted-by":"publisher","DOI":"10.1111\/wrr.12294"},{"key":"e_1_2_9_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjsurg.2006.07.010"},{"key":"e_1_2_9_23_1","first-page":"83","article-title":"Topical platelet\u2010derived growth factor vs placebo therapy of diabetic foot ulcers offloaded with windowed casts: a randomized, controlled trial","volume":"27","author":"Ma C","year":"2015","journal-title":"Wounds"},{"key":"e_1_2_9_24_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1742-481X.2009.00641.x"},{"key":"e_1_2_9_25_1","doi-asserted-by":"publisher","DOI":"10.2337\/diacare.18.1.64"},{"key":"e_1_2_9_26_1","doi-asserted-by":"publisher","DOI":"10.4103\/0976-9668.136160"},{"key":"e_1_2_9_27_1","doi-asserted-by":"publisher","DOI":"10.2337\/diacare.26.6.1856"},{"key":"e_1_2_9_28_1","first-page":"186","article-title":"A phase III study to evaluate the safety and efficacy of recombinant human epidermal growth factor (REGEND\u2122 150) in healing diabetic wounds","volume":"18","author":"Viswanathan V","year":"2006","journal-title":"Wounds"},{"key":"e_1_2_9_29_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1524-475X.1999.00335.x"},{"key":"e_1_2_9_30_1","doi-asserted-by":"publisher","DOI":"10.2337\/diacare.21.5.822"},{"key":"e_1_2_9_31_1","doi-asserted-by":"publisher","DOI":"10.1684\/ejd.2009.0750"},{"key":"e_1_2_9_32_1","doi-asserted-by":"publisher","DOI":"10.2217\/14750708.2.5.759"},{"key":"e_1_2_9_33_1","first-page":"80","article-title":"Use of a platelet\u2010derived growth factor gel in chronic diabetic foot ulcers","volume":"12","author":"Agrawal RP","year":"2009","journal-title":"Diabet Foot J"},{"key":"e_1_2_9_34_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.diabres.2008.10.005"},{"key":"e_1_2_9_35_1","first-page":"69","article-title":"Sodium carboxymethylcellulose aqueous\u2010based gel vs. becaplermin gel in patients with nonhealing lower extremity diabetic ulcers","volume":"10","author":"D'Hemecourt PA","year":"1998","journal-title":"Wounds"},{"key":"e_1_2_9_36_1","doi-asserted-by":"publisher","DOI":"10.12968\/jowc.2008.17.1.27917"},{"key":"e_1_2_9_37_1","first-page":"141","article-title":"Efficacy of recombinant human platelet derived growth factor (rhPDGF) based gel in diabetic foot ulcers: a randomized, multicenter, double blind, placebo controlled study in India","volume":"17","author":"Hardikar JV","year":"2005","journal-title":"Wounds"},{"key":"e_1_2_9_38_1","first-page":"133","article-title":"Effects of transforming growth factor +2 on wound healing in diabetic foot ulcers: a randomized controlled safety and dose\u2010ranging trial","volume":"2","author":"Robson MC","year":"2002","journal-title":"J Appl Res"},{"key":"e_1_2_9_39_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0939-4753(04)80029-2"},{"key":"e_1_2_9_40_1","doi-asserted-by":"publisher","DOI":"10.1097\/01.prs.0000222526.21512.4c"},{"key":"e_1_2_9_41_1","doi-asserted-by":"publisher","DOI":"10.1248\/jhs.54.432"},{"key":"e_1_2_9_42_1","doi-asserted-by":"publisher","DOI":"10.1186\/1741-7015-9-79"},{"key":"e_1_2_9_43_1","first-page":"133","article-title":"The attractiveness of network meta\u2010analysis: a comprehensive systematic and narrative review","volume":"7","author":"Greco T","year":"2015","journal-title":"Heart Lung Vessel"},{"key":"e_1_2_9_44_1","doi-asserted-by":"publisher","DOI":"10.1054\/bjps.2000.3525"},{"key":"e_1_2_9_45_1","doi-asserted-by":"publisher","DOI":"10.1172\/JCI115048"},{"key":"e_1_2_9_46_1","doi-asserted-by":"publisher","DOI":"10.1590\/S1555-79602013000100004"},{"key":"e_1_2_9_47_1","doi-asserted-by":"publisher","DOI":"10.1177\/1534734616645444"},{"key":"e_1_2_9_48_1","doi-asserted-by":"publisher","DOI":"10.3109\/08977194.2015.1031898"},{"key":"e_1_2_9_49_1","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1186\/2050-6511-14-44","article-title":"Active post\u2010marketing surveillance of the intralesional administration of human recombinant epidermal growth factor in diabetic foot ulcers","volume":"14","author":"Year\u2010Alos I","year":"2013","journal-title":"BMC Pharmacol Toxicol"},{"key":"e_1_2_9_50_1","doi-asserted-by":"publisher","DOI":"10.4239\/wjd.v5.i4.546"}],"container-title":["British Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fbcp.13470","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/bcp.13470","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,26]],"date-time":"2023-09-26T16:25:47Z","timestamp":1695745547000},"score":1,"resource":{"primary":{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/10.1111\/bcp.13470"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,1,5]]},"references-count":49,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2018,3]]}},"alternative-id":["10.1111\/bcp.13470"],"URL":"https:\/\/doi.org\/10.1111\/bcp.13470","archive":["Portico"],"relation":{},"ISSN":["0306-5251","1365-2125"],"issn-type":[{"value":"0306-5251","type":"print"},{"value":"1365-2125","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,1,5]]}}}